{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/67fbe5f67b4fe9379bcfb2cf/69f0f28f526757e10b5c0d24?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Episode 4: Smart drugs, dumb trials: rethinking the foundations of drug development","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/67fbe5f67b4fe9379bcfb2cf/1777398202664-58ae1c3a-6690-4eb9-8237-38a7227d5d1a.jpeg?height=200","description":"<p>&nbsp;</p><p>In this episode, host Nicola Hill, is joined by Professor Maddie Parsons, Dean of Research Excellence Frameworks at King’s College London, and Dr Graham Price, Head of Global Clinical Development at UCB, to examine whether today’s trials are fit for tomorrow’s science.</p><p>&nbsp;</p><p>Listen to our guests unpick the tensions in modern drug development from conservative endpoints, missed opportunities and lack of integration across clinical and scientific disciplines. Can smarter design, better data sharing, and deeper collaboration unlock the future of precision medicine?</p><p>&nbsp;</p><p>This podcast is produced and funded by UCB.</p><p>&nbsp;</p><p>Hosted on Acast. See&nbsp;<a href=\"https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Facast.com%2Fprivacy&amp;data=05%7C02%7Cpolly%40broadcastrevolution.co.uk%7C55232ab589fc485246dd08dea510a598%7Cee4bcdbbdf2c4475aa14f299fd60aaaf%7C0%7C0%7C639129688127370872%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=108%2BIA3rptKr4WdkzcW6CfedFyCYhw6Oag4DjYR6SdQ%3D&amp;reserved=0\" rel=\"noopener noreferrer\" target=\"_blank\"><u>acast.com/privacy</u></a>&nbsp;for more information.</p><p><strong>&nbsp;</strong></p><p>GL-OT-2600003 – March 2026</p>","author_name":"UCB Biopharma "}